Scribe Therapeutics, a biotech firm focused on gene-editing therapies for heart conditions, made a strong debut on the public market, with shares soaring 44% on their first trading day. Originally set to market 7.15 million shares at $13 to $15 each, Scribe ultimately sold 8.58 million shares at the top of that range, raising $128.7 million. Significant backing from investors like Eli Lilly and Sanofi highlights strong interest in gene-editing solutions for chronic diseases. Although Scribe is not yet profitable, it plans to use IPO proceeds to advance its clinical programs, with initial trial results expected by mid-2027.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.briefs.co/news/gene-editing-biotech-scribe-jumps-44-in-market-debut-targets/
